Phase 3 melanoma vaccine cuts recurrence or death risk by 42%
Sponsor-reported phase 3 INTerpath-001 data show intismeran plus pembrolizumab reduced melanoma recurrence or death risk by 42% and distant metastasis or death risk by 38%.
Topic
Intismeran
Topic
Intismeran
Personalized mRNA vaccine cuts melanoma recurrence or death risk by 42%
Intismeran plus Keytruda cut recurrence or death risk 42% in 1,137 resected melanoma patients; 82% reported no recurrence at two…
Personalized melanoma vaccine cuts recurrence or death risk by 42%
Intismeran plus pembrolizumab lowered the composite risk of melanoma recurrence or death by 42% in an international study of 1,13…